Effectiveness of ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3893-3903

  Scotlandi, Katia ^a   Perdichizzi, Stefania ^a   Manara, Maria Cristina ^a   Serra, Massimo ^a   Benini, Stefania ^a   Cerisano, Vanessa ^a   Strammiello, Rosaria ^a   Mercuri, Mario ^b   Reverter Branchat, Gemma ^a   Faircloth, Glynn ^c   D'Incalci, Maurizio ^d   Picci, Piero ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c PharmaMar USA Inc   (United States)

^d Dipartimento di Oncologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; METHOTREXATE; TRABECTEDIN; VINCRISTINE;

APOPTOSIS; ARTICLE; BONE DEVELOPMENT; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; EWING SARCOMA; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL DIFFERENTIATION; DIOXOLES; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; NUCLEAR PROTEINS; OSTEOSARCOMA; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; SARCOMA, EWING'S; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036895987     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Campanacci, M. Bone and Soft Tissue Tumors, 2nd Ed. Wien, Austria: Springer-Verlag, 1999.
2. Bramwell, V. H. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin. Oncol., 24: 561-571, 1997.
3. Bacci, G., Toni, A., Avella, M., Manfrini, M., Sudanese, A., Ciaroni, D., Boriani, S., Emiliani, E., and Campanacci, M. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy. Cancer (Phila.), 63: 1477-1486, 1988.
4. Burgert, E. O., Nesbit, M. E., Garnsey, L. A., Gehan, E. A., Herrmann, J., Vietti, T. J., Cangir, A., Tefft, M., Evans, R., Thomas, P., Askin, F. B., Kissane, J. M., Pritchard, D. J., Neff, J., Makley, J. T., and Gilula, L. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J. Clin. Oncol., 8: 1514-1524, 1990.
5. Paulussen, M., Ahrens, S., Dunst, J., Winkelmann, W., Exner, G. U., Kotz, R., Amann, G., Dockhorn-Dworniczak, B., Harms, D., Müller-Weihrich, S., Welte, K., Kornhuber, B., Janka-Schaub, G., Göbel, U., Treuner, J., Voûte, P. A., Zoubek, A., Gadner, H., and Jürgens, H. Localized Ewing tumor of bone: Final results of the cooperative Ewing's sarcoma study CESS 86. J. Clin. Oncol., 19: 1818-1829, 2001.
6. Harris, M. B., Gieser, P., Goorin, A. M., Ayala, A., Shochat, S. J., Ferguson, W. S., Holbrook, T., and Link, M. P. Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group Study. J. Clin. Oncol., 16: 3641-3648, 1998.
7. Paulussen, M., Ahrens, S., Craft, A. W., Dunst, J., Frohlich, B., Jabar, S., Rube, C., Winkelmann, W., Wissing, S., Zoubek, A., and Jürgens, H. Ewing's tumors with primary lung metastases: Survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J. Clin. Oncol., 16: 3044-3052, 1998.
8. Souhami, R. L., Craft, A. W., Van der Eijken, J. W., Nooij, M., Spooner, D., Bramwell, V. H., Wierzbicki, R., Malcom, A. J., Kirk-patrick, A., Uscinska, B. M., Van Glabbeke, M., and Machin, D. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet, 350: 911-917, 1997.
9. Bruland, Ø. S., and Pihl, A. On the current management of osteosarcoma: A critical evaluation and a proposal for a modified treatment strategy. Eur. J. Cancer, 11: 1725-1731, 1997.
10. Ferguson, W. S., and Goorin, A. M. Current treatment of osteosarcoma. Cancer Investig., 19: 292-315, 2001.
11. Bacci, G., Picci, P., Ferrari, S., Mercuri, M., Brach del Prever, A., Rosito, P., Barbieri, E., Tienghi, A., and Forni, C. Neoadjuvant chemotherapy for Ewing's sarcoma of bone. No benefit observed after adding iphosphamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase. Results of two sequential studies. Cancer (Phila.), 6: 1174-1183, 1998.
12. Craft, A., Cotterill, S., Malcolm, A., Spooner, D., Grimer, R., Souhami, R., Imeson, J., and Lewis, I. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J. Clin. Oncol., 16: 3628-3633, 1998.
13. Meyers, P. A., Krailo, M. D., Ladnyi, M., Chan, K-W., Sailer, S. L., Dickman, P. S., Baker, D. L., Davis, J. H., Gerbing, R. B., Grovas, A., Herzog, C. E., Lindsley, K. L., Liu-Mares, W., Nachman, J. B., Sieger, L., Wadman, J., and Gorlick, R. G. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J. Clin. Oncol., 19: 2812-2820, 2001.
14. Pommier, Y., Kohlhagen, G. Bailly, C., Waring, M., Mazumder, A., and Kohn, K. W. DANN sequence- and structure-selective alkylation of guanine N2 in the DANN minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry, 35: 13303-13309, 1996.
15. Takebayashi, Y., Pourquier, P., Yoshida, A., Kohlhagen, G., and Pommier, Y. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. USA, 96: 7196-7201, 1999.
16. Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G., D'Incalci, M., and Mantovani, R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc. Natl. Acad. Sci. USA, 97: 6780-6784, 2000.
17. Takebayashi, Y., Pourquier, P., Zimonjic, D. B., Nakayama, K., Emmert, S., Ueda, T., Urasaki, Y., Kanzaki, A., Akiyama, S-I., Popescu, N., Kraemer, K. H., and Pommier, Y. Antiproliferative activity of ectinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med., 7: 961-966, 2001.
18. Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., and D'Incalci, M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer, 37: 97-105, 2001.
19. Damia, G., Silvestri, S., Carcassa, L., Filiberti, L., Faircloth, G. T., Liberi, G., Foiani, M., and D'Incalci, M. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int. J. Cancer, 92: 583-588, 2001.
20. Izbicka, E., Lawrence, R., Raymond, E., Eckhardt, G., Faircloth, G., Jimeno, J., Clark, G., and Von Hoff, D. D. In vitro antitumor activity of the novel marine agent ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol., 9: 981-987, 1998.
21. Valoti, G., Nicoletti, M. I., Pellegrino, A., Jimeno, J., Hendriks, H., D'Incalci, M., Faircloth, G., and Gavazzi, R. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res., 4: 1977-1983, 1998.
22. Ghielmini, M., Colli, E., Erba, E., Bergamaschi, D., Pampallona, S., Jimeno, J., Faircloth, G., and Sessa, C. In vitro schedule-dependency of myelotoxicity and cytotoxicity of ecteinascidin 743 (ET-743). Ann. Oncol., 9: 989-993, 1998.
23. Hendriks, H. R., Fiebig, H. H., Giavazzi, R., Langdon, S. P., Jimeno, J. M., and Faircloth, G. T. High antitumor activity of ET743 against human tumor xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann. Oncol., 10: 1233-1240, 1999.
24. van Kesteren, C., Cvitkovic, E., Taamma, A., Lopez-Lazaro, L., Jimeno, J. M., Guzman, C., Mathot, R. A. A., Schellens, J. H. M., Misset, J-L., Brain, E., Hillebrand, M. J. X., Rosing, H., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a Phase I dose-finding study. Clin. Cancer Res., 6: 4725-4732, 2000.
25. Li, W. W., Takahashi, N., Jhanwar, S., Cordon-Cardo, C., Elisseyeff, Y., Jimeno, J., Faircloth, G., and Bertino, J. R. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: Identification of ecteinascidin-743 as a potent cytotoxic agent. Clin. Cancer Res., 7: 2908-2911, 2001.
26. Takahashi, N., Li, W. W., Banerjee, D., Scotto, K. W., and Bertino, J. R. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin. Cancer Res., 7: 3251-3257, 2001.
27. Maki, R. Sarcoma. Oncologist. 6: 333-337, 2001.
28. Benini, S., Baldini, N., Manara, M. C., Chano, T., Serra, M., Rizzi, S., Lollini, P-L., Picci, P., and Scotlandi, K. Redundancy of autocrine loops in human osteosarcoma cells. Int. J. Cancer, 80: 581-588, 1999.
29. Manara, M. C., Perbal, B., Benini, S., Strammiello, R., Cerisano, V., Perdichizzi, S., Serra, M., Astolfi, A., Bertoni, F., Alami, J., Yeger, H., Picci, P., and Scotlandi, K. The expression of ccn3(nov) gene in musculoskeletal tumors. Am. J. Pathol., 160: 849-859, 2002.
30. Scotlandi, K., Manara, M. C., Serra, M., Benini, S., Maurici, D., Caputo, A., De Giovanni, C., Lollini, P-L., Nanni, P., Picci, P., Campanacci, M., and Baldini, N. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 18: 739-746, 1999.
31. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
32. Chou, T. C., Riedeout, D., Chou, J., and Bertino, J. R. Chemotherapeutic synergism, potential and antagonism. In: R. Dulbecco (ed.), Encyclopedia of Human Biology, Vol. 2, pp. 371-379, San Diego, CA: Academic Press, 1991.
33. Erba, E., Bergamaschi, D., Bassano, L., Ronzoni, S., Di Liberti, G., Muradore, I., Vignati, S., Faircloth, G., Jimeno, J., and D'Incalci, M. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to ecteinascidin-743 (ET-743). Br. J. Cancer, 82: 1732-1739, 2000.
34. Stein, G. S., Lian, J. B., and Owen, T. A. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J., 4: 3111-3123, 1990.
35. Rinehart, K. L., Holt, T. G., Fregeau, N. L., Stroh, J. G., Keifer, P. A., Li, L. H., and Martin, D. G. Ecteinascidins 729, 743, 745, 759A, 759B and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J. Org. Chem., 55: 4512-4515, 1990.
36. Delaloge, S., Yovine, A., Taamma, A., Riofrio, M., Brain, E., Raymond, E., Cottu, P., Goldwasser, F., Jimeno, J., Misset, J. L., Marty, M., and Cvitkovic, E. Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J. Clin. Oncol., 19: 1248-1255, 2001.
37. Taamma, A., Misset, J. L., Riofrio, M., Guzman, C., Brain, E., Lopez Labaro, L., Rosine, H., Jimeno, J. M., and Cvitkovic, E. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol., 19: 1256-1265, 2001.
38. Ryan, D. P., Supko, J. G., Eder, J. P., Seiden, M. V., Demetri, G., Lynch, T. J., Fischman, A. J., Davis, J., Jimeno, J., and Clark, J. W. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin. Cancer Res., 7: 231-242, 2001.
39. Villalona-Calero, M. A., Eckhardt, S. G., Weiss, G., Hidalgo, M., Beijnen, J. H., van Kesteren, C., Rosing, H., Campbell, E., Kraynak, M., Lopez-Lazaro, L., Guzman, C., Von Hoff, D. D., Jimeno, J., and Rowinsky, E. K. A Phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin. Cancer Res., 8: 75-85, 2002.
40. Jin, S., Gorfajn, B., Faircloth, G., and Scotto, K. W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl. Acad. Sci. USA, 97: 6775-6779, 2000.
41. Synold, T. W., Dussault, I., and Forman, B. M. The orphan nuclear receptor SXR co-ordinately regulates drug metabolism and efflux. Nat. Med., 7: 584-590, 2001.
42. Abolhoda, A., Wilson, A. E., Ross, H., Danenberg, P. V., Burt, M., and Scotto, K. W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin. Cancer Res., 5: 3353-3356, 1999.
43. Baldini, N., Scotlandi, K., Barbanti-Brodano, G., Manara, M. C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M., and Serra, M. Expression of P-glycoprotein in high grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med., 333: 1380-1385, 1995.
44. Chan, H. S., Grogan, T. M., Haddad, G., DeBoer, G., and Ling, V. P-glycoprotein expression: Critical determinant in the response to osteosarcoma chemotherapy. J. Natl. Cancer Inst. (Bethesda), 89: 1706-1715, 1997.
45. Baldini, N., Scotlandi, K., Serra, M., Picci, P., Bacci, G., Sottili, S., and Campanacci, M. P-glycoprotein expression in osteosarcoma: A basis for risk-adapted adjuvant chemotherapy. J. Orthop. Res., 17: 629-632, 1999.